2017年5月31日

> Atonomics宣布CE標記跟蹤脂質測試麵板×Atonomics宣布CE標記跟蹤脂質測試麵板2017-05-31 14:00哥本哈根,丹麥,5月31日,2017年跟蹤是一個快速,從實驗室準確自我測試裝置測量健康和疾病生物標誌物跟蹤脂質麵板措施從指尖血膽固醇指標量化實驗室標準結果提供了在幾分鍾內脂質麵板和程序可以協助監測心血管風險而不需要將血樣送到中央實驗室Atonomics / S,一個消費者醫療診斷公司提供個人中心實驗室標準數據,今天宣布它的第一個商業產品的CE標誌,脂質測試小組在其專有跟蹤平台。跟蹤,個人生物標誌物的設備,是一種破壞性的自我測試平台準確,成本低,易於使用的診斷。脂質麵板決定總膽固醇,HDL(高密度脂質),LDL(低密度脂質)和甘油三酯水平從指尖血與量化標準實驗室結果幾分鍾內提供。可以使用簡單的墨盒測試監控的有效性的飲食,生活方式改變和藥物降低膽固醇心血管風險的一個重要標誌。該設備將與方便的讀出和跟蹤應用程序。“我們很高興推出的第一個產品後證明,我們可以實現中央實驗室精度在小和用戶友好的格式適合即時應用程序。雖然最初的CE標誌是體外診斷(試管)專業使用,自我測試的CE標誌是針對今年晚些時候,它將使我們為家用市場跟蹤直接消費者,”首席執行官Thomas Warthoe說。該公司計劃推出一係列的預防和疾病標記測試管道產品,包括糖化血紅蛋白,長期糖尿病措施,c反應蛋白,一個關鍵炎症標記,維生素水平,監測飲食控製遺傳疾病和其他慢性疾病監測參數。通過使用平台的方法和標準測定化學反應,實現新的測試通常可以在幾個月內完成。“技術和監管部門的批準後我們的平台技術通過多渠道合作我們現在駕駛商業吸收。 Beyond professional IVD and companion diagnostics pharma channels, we see rapidly growing interest in consumer facing diagnostics. Trace is well positioned to become a leading disruptive enabler in digital health," said Oliver Hofmann, CBO. Order online the first regulatory approved scientifically accurate personal medical diagnostic device: http://www.atonomics.com About Atonomics Atonomics is a consumer medical diagnostics company that has developed Trace, a self-testing device for measuring wellness and disease markers related to lifestyle and chronic disease management. Key differentiation versus competitors is the combined offering of high accuracy AND low cost, as enabled by use of a proprietary passive blood filtration approach and proven standard assay chemistries. The resulting easy-to-use device is ideally positioned for screening and monitoring applications in an outpatient setting including pharmacies, health kiosks and home use. About Trace Lipids Trace™ determines total cholesterol, HDL (high density lipids), LDL (low density lipids) and triglycerides levels from a finger prick of blood with quantitative lab standard results provided within minutes. According to WHO, raised total cholesterol is a major cause of disease burden and key risk factor for heart disease and stroke. Raised cholesterol is estimated to cause 2.6m deaths per annum with a global prevalence of 39%, increased to 54% in Europe. In OECD countries ~9% of the adult population is on cholesterol lowering statin medication, with up to one in five suffering from side effects. Alternative cholesterol lowering approaches include diet change and exercise. PoC lipids testing market was $200m in 2014, estimated to grow to >$280m by 2022 (Grand View Research).